Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance.
about
Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative NeoplasmsTargeting the Pim kinases in multiple myelomaThe PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches.FLT3-ITD induces expression of Pim kinases through STAT5 to confer resistance to the PI3K/Akt pathway inhibitors on leukemic cells by enhancing the mTORC1/Mcl-1 pathway.Novel Therapies for Myelofibrosis.Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies.
P2860
Q26766319-0B46F7BF-68B5-4398-804A-F4D70A646653Q26799499-07600979-D21A-4CB6-8DF8-355797D10019Q36545566-E346CFF9-B940-4721-8650-14D20F36FFE6Q47102210-9DC0BF1B-3BD0-44D8-8732-30491A257E7CQ52366350-2DFD456E-0C73-4796-AFA6-136BF7F7BB08Q52817185-705571D9-171B-4592-B800-4C6DE6C619AAQ55496770-EC62B8A8-0B31-439C-8EC9-062B17531744
P2860
Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Combination of PIM and JAK2 in ...... and overcomes drug resistance.
@en
type
label
Combination of PIM and JAK2 in ...... and overcomes drug resistance.
@en
prefLabel
Combination of PIM and JAK2 in ...... and overcomes drug resistance.
@en
P2093
P2860
P356
P1433
P1476
Combination of PIM and JAK2 in ...... and overcomes drug resistance.
@en
P2093
Anlai Wang
Carlos Garcia-Echeverria
Christoph Lengauer
Claude Barberis
Dmitri Wiederschain
Francisco Adrian
Hong Cheng
Jack Pollard
James Watters
P2860
P304
P356
10.18632/ONCOTARGET.1951
P407
P577
2014-05-01T00:00:00Z